a note on preparing a new drug application and a biologics license application
This is a PDF document titled "A Note on Preparing a New Drug Application and a Biologics License Application.pdf" created in September 2025. It is a detailed technical note prepared by Harvard Business School faculty and industry experts that explains the regulatory frameworks, submission requirements, and procedural details for New Drug Applications (NDA) and Biologics License Applications (BLA) to the U.S. Food and Drug Administration (FDA). The document covers distinctions between drugs and biologics, the electronic Common Technical Document (eCTD) format, dossier composition, data standards, project management, and FDA review processes. It serves as an educational resource for regulatory affairs professionals, pharmaceutical developers, and students in drug development and regulatory science.
Questions this document answers
The FDA reviews and approves NDAs and BLAs for new drugs and biologics, respectively.
Its purpose is to obtain FDA approval to market a new drug.
It seeks FDA approval to commercially distribute biologic products.
It ensures consistency and compliance in regulatory submissions.
It includes application forms, labels, and post-market plans.